The Union Ministry of Health and Family Welfare has proposed expanding India's network of authorised import gateways for medicines, medical devices and cosmetics through an amendment to Rule 43A of the Drugs Rules, 1945. The proposal aims to improve import logistics, reduce transportation distances and strengthen the supply chain for healthcare products.
The proposed amendment, announced on November 3, includes additional Inland Container Depots (ICDs), a Special Economic Zone (SEZ) and an international airport in the list of authorised entry points for healthcare product imports.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Proposal to expand authorised import gateways for medicines, medical devices and cosmetics.
Location: India.
Authority/Organisation: Union Ministry of Health and Family Welfare.
Action Taken: Proposed an amendment to Rule 43A of the Drugs Rules, 1945, adding inland depots, an SEZ and an international airport.
Impact: Could improve import logistics, reduce inland transportation distances and support more efficient healthcare product distribution.
The proposed additions include ICD Sonipat, Piyala and Harsaru in Haryana; ICD Dadri in Uttar Pradesh; ICD Gandhidham/Mundra in Gujarat; ICD Sanath Nagar and Thimmapur in Hyderabad, Telangana; and ICD Whitefield in Bengaluru, Karnataka.
The proposal also includes SEZ Bommasandra in Karnataka and Noida International Airport in Uttar Pradesh as an additional entry point for the import of drugs by air.
These locations would supplement the existing authorised import network, which includes ICDs at Dhannad and Tihi in Indore, Madhya Pradesh, along with airports already notified for drug imports.
Editorial Analysis
Why This Matters
India's pharmaceutical and medical-device supply chains depend on efficient import and distribution systems. Delays in clearing imported consignments can affect inventory planning, manufacturing operations and the movement of products to warehouses and distributors. Adding more authorised entry points could give importers greater flexibility in choosing locations closer to their facilities. This may reduce inland transportation requirements and help businesses manage logistics costs more efficiently. The proposal could also benefit healthcare supply chains by supporting smoother movement of medicines, medical devices and cosmetics across different parts of the country. However, the proposed changes do not automatically mean that product prices will fall or that medicines will become immediately cheaper. Their practical impact will depend on implementation, logistics arrangements and how businesses use the additional gateways.
Rule 43A of the Drugs Rules, 1945, specifies the authorised ports, airports, railway stations, road crossings and other entry points through which drugs can be imported into India. The proposed changes seek to make the import process more convenient for businesses by allowing consignments to be cleared closer to manufacturing facilities, warehouses and distribution centres.
For importers, the expansion could reduce the distance that imported consignments need to travel after arriving in the country. Shorter inland transportation routes may help optimise logistics costs, improve operational convenience and reduce delays in moving healthcare products to distribution networks.
The proposal is also relevant to India's pharmaceutical and medical-device supply chains, where efficient movement of imported inputs and finished products can influence inventory management and distribution timelines.
The Ministry expects the proposed expansion to strengthen supporting infrastructure for healthcare imports and contribute to a more efficient supply chain. It also aims to promote ease of doing business while facilitating the availability of essential healthcare products across different regions.
However, the proposal has not yet become a final implemented amendment. The Ministry has invited objections and suggestions from stakeholders before proceeding with the proposed regulatory change.
Stakeholders can submit their comments to the Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, at Kartavya Bhawan-1, New Delhi, or through the official email address provided in the government notification.
The final impact will depend on the completion of the consultation process and the subsequent notification of the amendment. Until then, the proposed locations should not be treated as newly authorised import gateways.
